Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Clin J Oncol Nurs ; 22(3): E85-E91, 2018 06 01.
Article in English | MEDLINE | ID: mdl-29781464

ABSTRACT

BACKGROUND: Psychosocial distress screening is a quality care standard in cancer care. Screening implementation may be facilitated by an educational program that uses goals to evaluate progress over time. OBJECTIVES: This article describes the content and design of the Screening for Psychosocial Distress Program (SPDP), reports on its delivery to 36 paired participants, and evaluates its effects on distress screening activities and goals. METHODS: The SPDP used a one-group pre-/post-test design. It was delivered at 2 workshops and 10 conference calls during a two-year period. Data on screening and goal achievement were collected at 6, 12, and 24 months. Data on the quality of dyads' relationships were collected at 24 months. FINDINGS: At 24 months, all 18 dyads had begun screening. Dyads reported working effectively together and being supportive of the other member of the dyad while achieving their goals for implementing psychosocial distress screening.


Subject(s)
Education, Medical/organization & administration , Neoplasms/psychology , Oncology Nursing/education , Oncology Nursing/methods , Quality of Life/psychology , Stress, Psychological/diagnosis , Stress, Psychological/therapy , Adult , Curriculum , Female , Humans , Male , Middle Aged , United States
2.
Psychooncology ; 27(5): 1364-1376, 2018 05.
Article in English | MEDLINE | ID: mdl-29749682

ABSTRACT

Worldwide, psychological and social issues in cancer were not the subject of scientific inquiry until the past two decades. Since then, a new subspecialty of oncology has evolved, psycho-oncology. It addresses two dimensions of cancer: the emotional responses of patients at all stages of disease, as well as their families and caretakers (psychosocial); and the pyschological, social and behavioral factors that may influence cancer morbidity and mortality (psychobiological). Obstacles to development have been the facts of small numbers of clinicians and investigators worldwide and the few valid assessment instruments and research methods available to the biomedical community. These obstacles are increasingly giving way to the louder demand of the public for maximal quality of life in cancer care. Psycho-oncology is attaining subspeciality status by presently bringing a set of clinical skills in counseling, behavioral and social interventions to oncology, by providing training curricula which teach basic knowledge and skills in the area, and through creating a body of research and scholarly information about clinically relevant issues in the care of patients with cancer. Since it is increasingly recognized that psychological, social and behavioral variables influence treatment outcome, attention will likely to continue to increase. The field must meet the challenges of the 1990's in psychosocial care and availability of services, support for training clinicians and investigators in psycho-oncology, and implementation of an exciting research agenda. The focus of new research will encourage collaborative investigations combining biological and psychosocial variables, quality of life research in clinical trials, controlled studies of psychotherapeutic, behavioral and psychopharmacologic research, and crosscultural studies that will examine differences in prevention and detection, health care systems, alternative therapies and meta analyses.


Subject(s)
Medical Oncology/history , Neoplasms/psychology , Psycho-Oncology/history , Psychophysiologic Disorders/history , Quality of Life , History, 19th Century , History, 20th Century , Humans , Neoplasms/history
3.
Psychooncology ; 27(3): 900-907, 2018 03.
Article in English | MEDLINE | ID: mdl-29239060

ABSTRACT

BACKGROUND: As the number of older adults in the United States continues to grow, there will be increasing demands on health care providers to address the needs of this population. Cancer is of particular importance, with over half of all cancer survivors older than 65 years. In addition, depression, pain, and fatigue are concerns for older adults with cancer and have been linked to poorer physical outcomes. METHODS: For this retrospective chart review, 1012 eligible participants were identified via a query of the Electronic Medical Record for all patients referred to 1 of 4 Survivorship Clinics at Memorial Sloan Kettering Cancer Center. All patients were between the ages of 30 to 55 (younger adults) and >65 (older adults). Depression was measured using the Patient Health Questionnaire-9 (PHQ-9). RESULTS: The overall rate of depression in this sample of adult cancer survivors was 9.3%. There were no differences in the rates of clinically significant depression (defined as PHQ-9 score ≥10) between younger and older adult cohorts. However, there was a small trend toward higher mean PHQ-9 scores in the younger adult cohort (3.42 vs 2.95; t = 1.763, P = .10). Women reported greater rates of depression and higher pain and fatigue scores. Hispanic/Latino patients also reported significantly greater rates of depression. CONCLUSION: There were no observed differences in depression between older and younger adult cancer survivors. Gender and ethnic discrepancies in depression were observed. Future research should focus on understanding the nature of these differences and targeting interventions for the groups most vulnerable to depression after cancer treatment.


Subject(s)
Cancer Survivors/statistics & numerical data , Depression/epidemiology , Fatigue/epidemiology , Pain/epidemiology , Adult , Age Factors , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Prevalence , Retrospective Studies , United States
4.
Cancer ; 123(21): 4092-4096, 2017 Nov 01.
Article in English | MEDLINE | ID: mdl-28817185

ABSTRACT

Financial burden from cancer treatment is increasingly being recognized as a threat to optimal access, quality, and outcomes of cancer care for patients. Although research in the area is moving at a fast pace, multiple questions remain unanswered, such as how to practically integrate the assessment and management of financial burden into routine health care delivery for patients with cancer. Although psychological distress screening for patients undergoing cancer treatment now is commonplace, the authors raise the provocative idea of universal screening for financial distress to identify and assist vulnerable groups of patients. Herein, the authors outline the arguments to support screening for financial burden in addition to psychological distress, examining it as an independent patient-reported outcome for all patients with cancer at various time points during their treatment. The authors describe the proximal and downstream impact of such a strategy and reflect on some challenges and potential solutions to help integrate this concept into routine cancer care delivery. Cancer 2017;123:4092-4096. © 2017 American Cancer Society.


Subject(s)
Cost of Illness , Financing, Personal/economics , Neoplasms/economics , Neoplasms/psychology , Stress, Psychological/diagnosis , Stress, Psychological/economics , Accreditation , Antineoplastic Agents/economics , Cancer Care Facilities , Drug Costs , Health Behavior , Humans , Immunotherapy/economics , Neoplasms/therapy , Quality of Life , Stress, Psychological/therapy , Surveys and Questionnaires
5.
Clin Adv Hematol Oncol ; 14(12): 999-1009, 2016 Dec.
Article in English | MEDLINE | ID: mdl-28212362

ABSTRACT

Psychological issues in the cancer setting are highly prevalent and well documented, and can lead to adverse outcomes. Several series of guidelines have been put forth to ensure that both psychological and psychiatric issues are addressed. The management of psychological issues in cancer is relevant for clinicians whose patients are identified clinically or via screening mechanisms with psychological or psychiatric sequelae from cancer. This review describes the psychological impact of cancer, distress screening as a triage mechanism, and the presentation and management of several specific comorbid psychological/psychiatric diagnoses in the oncology setting.


Subject(s)
Mental Disorders/prevention & control , Neoplasms/psychology , Disease Management , Humans , Prevalence , Risk Factors
6.
Psychosomatics ; 56(6): 630-3, 2015.
Article in English | MEDLINE | ID: mdl-26674482

ABSTRACT

OBJECTIVE: The purpose of this article is to examine and appreciate the contributions of George Libman Engel, MD, to psychosomatic medicine. CONCLUSION: Engel was a prolific researcher, medical educator, and writer who championed the biopsychosocial model, which has been widely embraced and practiced in psychiatry and medicine to this day. In the late 1970s, when Engel published his seminal article on the biopsychosocial model, the dominant model of medicine was still the biomedical model. This model considered the most important and scientifically sound aspects of patient history to be those that could be easily quantified, such as laboratory values. The biomedical model left no room for the psychosocial aspects, such as the patient's relationships and social status, to be integrated into patient care. Though many had expressed dissatisfaction with the biomedical model and suspected that it was too 1 dimensional to provide adequate patient care, Engel was among the first to propose a replacement model. Furthermore, he stipulated that there is a scientific necessity to consider psychosocial aspects of patient history to provide the most complete diagnoses and treatment plan. Along with his biopsychosocial approach to the patient, Engel also contributed heavily to research and to education of medical students. His legacy is one of compassionate, scientific doctoring.


Subject(s)
Psychosomatic Medicine/history , History, 20th Century , Humans , Male , United States
8.
J Oncol Pract ; 11(3): e413-20, 2015 May.
Article in English | MEDLINE | ID: mdl-25758447

ABSTRACT

PURPOSE: The American College of Surgeons Commission on Cancer (CoC) has set psychosocial distress screening as a new patient care standard to be met by 2015. The standard requires CoC-accredited cancer centers to integrate and monitor distress screening and, when needed, refer patients to psychosocial health care services. We describe the uptake of distress screening reported by applicants to a distress screening cancer education program and the degree of and barriers to implementation of distress screening programs reported by selected participants. MATERIALS AND METHODS: This cross-sectional study collected quantitative data online from applicants to the program between August 1 and November 15, 2013, described by frequencies, percentages, and measures of central tendency, and qualitative data in person from accepted participants on February 13, 2014, analyzed using an integrated approach to open-ended data. RESULTS: Applications were received from 70 institutions, 29 of which had started distress screening. Seven of 18 selected applicant institutions had not begun screening patients for distress. Analysis of qualitative data showed that all participants needed to create buy-in among key cancer center staff, including oncologists; to decide how to conduct screening in their institution in a way that complied with the standard; and to pilot test screening before large-scale rollout. CONCLUSION: Fourteen months before the compliance deadline, fewer than half of applicant institutions had begun distress screening. Adding implementation strategies to mandated quality care standards may reduce uncertainty about how to comply. Support from key staff members such as oncologists may increase uptake of distress screening.


Subject(s)
Cancer Care Facilities , Health Plan Implementation/methods , Mass Screening/methods , Medical Oncology/methods , Neoplasms/psychology , Stress, Psychological/diagnosis , Cancer Care Facilities/standards , Cross-Sectional Studies , Education, Medical, Continuing , Health Plan Implementation/standards , Humans , Inservice Training , Mass Screening/standards , Medical Oncology/standards , Neoplasms/complications , Neoplasms/diagnosis , Neoplasms/therapy , Predictive Value of Tests , Program Development , Program Evaluation , Quality Improvement , Quality Indicators, Health Care , Referral and Consultation , Stress, Psychological/psychology , Stress, Psychological/therapy , United States
9.
Psychooncology ; 24(6): 683-90, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25345591

ABSTRACT

OBJECTIVE: Patients diagnosed with lung cancer report high levels of stigma and psychological distress. This study examined posttraumatic growth among lung cancer survivors as a potential buffer against this relationship between stigma and psychological distress and examined how these relationships differed by the timing of quitting smoking (pre versus post-diagnosis). METHODS: Stages IA and IB non-small-cell lung cancer survivors (N = 141) who were former smokers, 1-6 years post-treatment, and had no evidence of disease completed standardized questionnaires assessing stigma, posttraumatic growth, timing of quitting smoking history, and psychological distress. RESULTS: Hierarchical linear regression and simple slope analyses indicated that among those who quit smoking prior to diagnosis (pre-diagnosis quitters), stigma had a positive association with psychological distress at high levels of posttraumatic growth (p = 0.003) and had a positive (but non-significant) association with psychological distress among those with low levels of posttraumatic growth (p = 0.167). Among those who quit smoking after diagnosis (post-diagnosis quitters), stigma had a positive association with psychological distress among those with low levels of posttraumatic growth (p = 0.004) but had no relationship among those with high levels of posttraumatic growth (p = 0.880). CONCLUSIONS: Findings indicate that posttraumatic growth buffers against the negative effects of stigma on psychological distress but only among post-diagnosis quitters. Future interventions could focus on fostering posttraumatic growth as a way to decrease the negative effects of stigma.


Subject(s)
Adaptation, Psychological , Carcinoma, Non-Small-Cell Lung/psychology , Lung Neoplasms/psychology , Smoking Cessation/psychology , Smoking , Social Stigma , Stress, Psychological/psychology , Aged , Anxiety/psychology , Depression/psychology , Female , Humans , Linear Models , Male , Middle Aged , Smoking Cessation/statistics & numerical data , Surveys and Questionnaires , Time Factors
10.
J Clin Oncol ; 32(15): 1605-19, 2014 May 20.
Article in English | MEDLINE | ID: mdl-24733793

ABSTRACT

PURPOSE: A Pan-Canadian Practice Guideline on Screening, Assessment, and Care of Psychosocial Distress (Depression, Anxiety) in Adults With Cancer was identified for adaptation. METHODS: American Society of Clinical Oncology (ASCO) has a policy and set of procedures for adapting clinical practice guidelines developed by other organizations. The guideline was reviewed for developmental rigor and content applicability. RESULTS: On the basis of content review of the pan-Canadian guideline, the ASCO panel agreed that, in general, the recommendations were clear, thorough, based on the most relevant scientific evidence, and presented options that will be acceptable to patients. However, for some topics addressed in the pan-Canadian guideline, the ASCO panel formulated a set of adapted recommendations based on local context and practice beliefs of the ad hoc panel members. It is recommended that all patients with cancer be evaluated for symptoms of depression and anxiety at periodic times across the trajectory of care. Assessment should be performed using validated, published measures and procedures. Depending on levels of symptoms and supplementary information, differing treatment pathways are recommended. Failure to identify and treat anxiety and depression increases the risk for poor quality of life and potential disease-related morbidity and mortality. This guideline adaptation is part of a larger survivorship guideline series. CONCLUSION: Although clinicians may not be able to prevent some of the chronic or late medical effects of cancer, they have a vital role in mitigating the negative emotional and behavioral sequelae. Recognizing and treating effectively those who manifest symptoms of anxiety or depression will reduce the human cost of cancer.


Subject(s)
Anxiety/diagnosis , Anxiety/therapy , Depression/diagnosis , Depression/therapy , Medical Oncology/standards , Neoplasms/complications , Societies, Medical/standards , Adolescent , Adult , Anxiety/etiology , Anxiety/psychology , Consensus , Cost of Illness , Depression/etiology , Depression/psychology , Emotions , Evidence-Based Medicine/standards , Humans , Neoplasms/psychology , Practice Patterns, Physicians'/standards , Predictive Value of Tests , Quality of Life , Treatment Outcome , United States , Young Adult
11.
Int Rev Psychiatry ; 26(1): 128-35, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24716506

ABSTRACT

Psychosocial oncology is a multi-disciplinary field of practice and, as a recently developed speciality, covers the psychological, social and behavioural dimensions of cancer. We describe the historical background and changing ethos in medical practice in order to understand factors that contributed to the emergence of this new discipline. Modern psychosocial oncology covers a number of topics; the diagnosis and management of psychological morbidity and distress across the cancer continuum from diagnosis through survivorship and, for some patients, terminal illness, the recognition that behaviour and lifestyle contribute to cancer risk and prognosis, the need to include families and carers alongside patients in a comprehensive model of supportive cancer care. Best practice, based on evidence and nationally and internationally accepted guidelines, is being integrated into national cancer plans, and services are briefly described. Future challenges include the need to recognize that the behavioural and mental health sciences have a role to play in comprehensive cancer care and that multi-disciplinary care, which includes psychosocial care, is the best model for ensuring patients needs are comprehensively and adequately met. The return of modern medicine to a more holistic person-focused ethos is needed in order to put the patient back into patient-centred cancer care.


Subject(s)
Interdisciplinary Studies , Medical Oncology/methods , Patient-Centered Care/methods , Psychiatry/methods , History, 20th Century , History, 21st Century , Humans , Medical Oncology/history , Patient-Centered Care/history , Psychiatry/history
12.
Psychooncology ; 23(2): 195-203, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24027194

ABSTRACT

BACKGROUND: The Distress Thermometer (DT) is widely recommended for screening for distress after cancer. However, the validity of the DT in men with prostate cancer and over differing time points from diagnosis has not been well examined. METHOD: Receiver operating characteristics analyses were used to evaluate the diagnostic accuracy of the DT compared with three commonly used standardised scales in two prospective and one cross-sectional survey of men with prostate cancer (n = 740, 189 and 463, respectively). Comparison scales included the Impact of Event Scale - Revised (IES-R, Study 1), the Hospital Anxiety and Depression Scale (HADS, Study 2) and the Brief Symptom Inventory-18 (BSI-18, Study 3). RESULTS: Study 1: the DT showed good accuracy against the IES-R at all time points (area under curves (AUCs) ranging from 0.84 to 0.88) and sensitivity was high (>85%). Study 2: the DT performed well against both the anxiety and depression subscales for HADS at baseline (AUC = 0.84 and 0.82, respectively), but sensitivity decreased substantially after 12 months. Study 3: validity was high for the anxiety (AUC = 0.90, sensitivity = 90%) and depression (AUC = 0.85, sensitivity = 74%) subscales of the BSI-18 but was poorer for somatization (AUC = 0.67, sensitivity = 52%). A DT cut-off between ≥3 and ≥6 maximised sensitivity and specificity across analyses. CONCLUSIONS: The DT is a valid tool to detect cancer-specific distress, anxiety and depression among prostate cancer patients, particularly close to diagnosis. A cut-off of ≥4 may be optimal soon after diagnosis, and for longer-term assessments, ≥3 was supported. © 2013 The Authors. Psycho-Oncology published by John Wiley & Sons, Ltd.


Subject(s)
Anxiety/diagnosis , Depression/diagnosis , Prostatic Neoplasms/psychology , Stress, Psychological/diagnosis , Adult , Aged , Aged, 80 and over , Anxiety/psychology , Area Under Curve , Depression/psychology , Humans , Male , Mass Screening , Middle Aged , Psychometrics/instrumentation , Reproducibility of Results , Sensitivity and Specificity , Stress, Psychological/psychology , Surveys and Questionnaires
13.
J Natl Compr Canc Netw ; 11(5 Suppl): 687-9, 2013 May.
Article in English | MEDLINE | ID: mdl-23704244

ABSTRACT

Many patients being treated for cancer have significant distress and often do not receive the attention they require. The psychosocial concerns of these patients are now better recognized and treated through psycho-oncology, which has become a multidisciplinary subspecialty of oncology concerned with the emotional responses of patients at all stages of disease, their families, and staff. In her presentation at the NCCN 18th Annual Conference, Dr. Jimmie C. Holland briefly reviewed the early role played by the NCCN as well as other national and international organizations in improving the psychosocial care of patients with cancer.


Subject(s)
Neoplasms/psychology , Neoplasms/therapy , Psychotherapy , Stress, Psychological , Humans , Outcome Assessment, Health Care , Practice Guidelines as Topic
14.
J Natl Compr Canc Netw ; 11(2): 190-209, 2013 Feb 01.
Article in English | MEDLINE | ID: mdl-23411386

ABSTRACT

The integration of psychosocial care into the routine care of all patients with cancer is increasingly being recognized as the new standard of care. These NCCN Clinical Practice Guidelines in Oncology for Distress Management discuss the identification and treatment of psychosocial problems in patients with cancer. They are intended to assist oncology teams identify patients who require referral to psychosocial resources and to give oncology teams guidance on interventions for patients with mild distress to ensure that all patients with distress are recognized and treated.


Subject(s)
Medical Oncology/standards , Neoplasms/psychology , Neoplasms/therapy , Stress, Psychological/etiology , Stress, Psychological/therapy , Clinical Trials as Topic , Humans , Practice Guidelines as Topic , Stress, Psychological/drug therapy , Stress, Psychological/psychology
15.
Psychosomatics ; 54(2): 111-4, 2013.
Article in English | MEDLINE | ID: mdl-23352050

ABSTRACT

BACKGROUND: Adolf Meyer, the first Professor of Psychiatry at Johns Hopkins, and Chief of the Phipps Clinic, brought a bevy of new ideas to clinical practice and to medical education. He used the word "psychobiology," which helped to establish psychosomatic medicine and formed the basis for Engel's "biopsychosocial" concept. OBJECTIVE: This paper aims to review the contributions of Adolf Meyer, who proposed that in studying patients, it was impossible to consider the mind and body separately. RESULTS: Adolf Meyer, through his insight and tenacity, promoted the integration of psychiatry and medicine in medical education and practice. CONCLUSION: By taking a closer look at the role of Meyer's work in relation to today's psychosomatic medicine, current challenges do not appear to be dramatically different from the issues faced a century ago.


Subject(s)
Psychiatry/history , Psychosomatic Medicine/history , History, 19th Century , History, 20th Century , Humans , United States
16.
Psychooncology ; 22(2): 315-23, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22021121

ABSTRACT

OBJECTIVES: This paper aims to investigate the effect of socioeconomic status, as measured by education, on the survival of breast cancer patients treated on 10 studies conducted by the Cancer and Leukemia Group B. METHODS: Sociodemographic data, including education, were reported by the patient at trial enrollment. Cox proportional hazards model stratified by treatment arm/study was used to examine the effect of education on survival among patients with early stage and metastatic breast cancer, after adjustment for known prognostic factors. RESULTS: The patient population included 1020 patients with metastatic disease and 5146 patients with early stage disease. Among metastatic patients, factors associated with poorer survival in the final multivariable model included African American race, never married, negative estrogen receptor status, prior hormonal therapy, visceral involvement, and bone involvement. Among early stage patients, significant factors associated with poorer survival included African American race, separated/widowed, post/perimenopausal, negative/unknown estrogen receptor status, negative progesterone receptor status, >4 positive nodes, tumor diameter >2 cm, and education. Having not completed high school was associated with poorer survival among early stage patients. Among metastatic patients, non-African American women who lacked a high school degree had poorer survival than other non-African American women, and African American women who lacked a high school education had better survival than educated African American women. CONCLUSIONS: Having less than a high school education is a risk factor for death among patients with early stage breast cancer who participated in a clinical trial, with its impact among metastatic patients being less clear. Post-trial survivorship plans need to focus on women with low social status, as measured by education.


Subject(s)
Breast Neoplasms/mortality , Social Class , Adult , Black or African American/statistics & numerical data , Aged , Breast Neoplasms/ethnology , Clinical Trials as Topic , Educational Status , Female , Humans , Middle Aged , Multivariate Analysis , Proportional Hazards Models , Risk Factors , Survival Rate , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...